Translation of genomics-guided RNA-based personalised cancer vaccines: Towards the bedside

British Journal of Cancer

Volumn 111, Issue 8, 2014, Pages 1469-1475

  Boisguerin V ^a,b   Castle, J C ^a   Loewer, M ^a   Diekmann, J ^a   Mueller, F ^a,b,c   Britten, C M ^a,d   Kreiter, S ^a   Tureci O ^a,e   Sahin, U ^a,b  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b BIONTECH AG   (Germany)

^c Theracode GmbH   (Germany)

^d Ribological GmbH   (Germany)

^e Ganymed Pharmaceuticals AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; RNA;

DRUG SCREENING; GENETICS; HUMAN; MUTATION; PERSONALIZED MEDICINE; TRANSLATIONAL RESEARCH;

CANCER VACCINES; DRUG EVALUATION, PRECLINICAL; HUMANS; INDIVIDUALIZED MEDICINE; MUTATION; RNA, NEOPLASM; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84908671756     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.820     Document Type: Review

References (41)

1. Abrams SI, Hand PH, Tsang KY, Schlom J (1996) Mutant ras epitopes as targets for cancer vaccines. Semin Oncol 23(1): 118-134.
2. Andersen RS, Thrue CA, Junker N, Lyngaa R, Donia M, Ellebaek E, Svane IM, Schumacher TN, Thor Straten P, Hadrup SR (2012) Dissection of T-cell antigen specificity in human melanoma. Cancer Res 72(7): 1642-1650.
3. Boegel S, Lower M, Schafer M, Bukur T, de Graaf J, Boisguerin V, Tureci O, Diken M, Castle JC, Sahin U (2013) HLA typing from RNA-Seq sequence reads. Genome Med 4(12): 102.
4. Britten CM, Singh-Jasuja H, Flamion B, Hoos A, Huber C, Kallen KJ, Khleif SN, Kreiter S, Nielsen M, Rammensee HG, Sahin U, Hinz T, Kalinke U (2013) The regulatory landscape for actively personalized cancer immunotherapies. Nat Biotechnol 31(10): 880-882.
5. CarboneDP,Ciernik IF,KelleyMJ, SmithMC, Nadaf S,KavanaughD, MaherVE, Stipanov M, Contois D, Johnson BE, Pendleton CD, Seifert B, Carter C, Read EJ, Greenblatt J, Top LE, Kelsey MI, Minna JD, Berzofsky JA (2005) Immunization with mutant p53-and K-ras-derived peptides in cancer patients: immune response and clinical outcome. J Clin Oncol 23(22): 5099-5107.
6. Castle JC, Biery M, Bouzek H, Xie T, Chen R,Misura K, Jackson S, Armour CD, Johnson JM, Rohl CA, Raymond CK (2010) DNA copy number, including telomeres and mitochondria, assayed using next-generation sequencing. BMC Genomics 11(1): 244.
7. Castle JC, Kreiter S, Diekmann J, Lower M, van de Roemer N, de Graaf J, Selmi A, Diken M, Boegel S, Paret C, Koslowski M, Kuhn AN, Britten CM, Huber C, Tureci O, Sahin U (2012) Exploiting the mutanome for tumor vaccination. Cancer Res 72(5): 1081-1091.
8. Diekmann J, Loewer M, Castle JC, Kreiter S, Tuereci O, Sahin U (2012) The T cell druggable genome. Eur Pharm Rev 17(4): 16-19.
9. Diken M, Kreiter S, Selmi A, Britten CM, Huber C, Tureci O, Sahin U (2011) Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation. Gene Ther 18(7): 702-708.
10. Diken M, Kreiter S, Selmi A, Tureci O, Sahin U (2013) Antitumor vaccination with synthetic mRNA: strategies for in vitro and in vivo preclinical studies. Methods Mol Biol 969: 235-246.
11. Fidler IJ (1973) Selection of successive tumour lines for metastasis. Nat New Biol 242(118): 148-149.
12. Garber K (2013) Melanoma combination therapies ward off tumor resistance. Nat Biotechnol 31(8): 666-668.
13. Hait WN, Hambley TW (2009) Targeted cancer therapeutics. Cancer Res 69(4): 1263-1267, discussion 1267.
14. Kanehisa M, Goto S (2000) KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28(1): 27-30.
15. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, Essahsah F, Fathers LM, Offringa R, Drijfhout JW,Wafelman AR, Oostendorp J, Fleuren GJ, van der Burg SH, Melief CJ (2009) Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 361(19): 1838-1847.
16. Kreiter S, Diken M, Selmi A, Diekmann J, Attig S, Husemann Y, Koslowski M, Huber C, Tureci O, Sahin U (2011a) FLT3 ligand enhances the cancer therapeutic potency of naked rna vaccines. Cancer Res 71: 6132-6142.
17. Kreiter S, Diken M, Selmi A, Tureci O, Sahin U (2011b) Tumor vaccination using messenger RNA: prospects of a future therapy. Curr Opin Immunol 23(3): 399-406.
18. Kreiter S, Konrad T, Sester M, Huber C, Tureci O, Sahin U (2007) Simultaneous ex vivo quantification of antigen-specific CD4 and CD8 T cell responses using in vitro transcribed RNA. Cancer Immunol Immunother 56(10): 1577-1587.
19. Kreiter S, Selmi A, Diken M, Koslowski M, Britten CM, Huber C, Tureci O, Sahin U (2010) Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res 70(22): 9031-9040.
20. Kuhn AN, Diken M, Kreiter S, Vallazza B, Tureci O, Sahin U (2011) Determinants of intracellular RNA pharmacokinetics: Implications for RNA-based immunotherapeutics. RNA Biol 8(1): 35-43.
21. Langmead B, Trapnell C, Pop M, Salzberg SL (2009) Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol 10(3): R25.
22. Larson DE, Harris CC, Chen K, Koboldt DC, Abbott TE, Dooling DJ, Ley TJ, Mardis ER, Wilson RK, Ding L (2012) SomaticSniper: identification of somatic point mutations in whole genome sequencing data. Bioinformatics 28(3): 311-317.
23. Lennerz V, Fatho M, Gentilini C, Frye RA, Lifke A, Ferel D,Wolfel C, Huber C, Wolfel T (2005) The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci USA 102(44): 16013-16018.
24. Li H, Durbin R (2009) Fast and accurate short read alignment with burrows-wheeler transform. Bioinformatics 25(14): 1754-1760.
25. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R (2009) The sequence alignment/map format and SAMtools. Bioinformatics 25(16): 2078-2079.
26. Löwer M, Renard BY, de Graaf J, Wagner M, Paret C, Kneip C, Tureci O, Diken M, Britten C, Kreiter S, Koslowski M, Castle JC, Sahin U (2012) Confidence-based somatic mutation evaluation and prioritization. PLoS Comput Biol 8(9): e1002714.
27. Lundegaard C, Lamberth K, Harndahl M, Buus S, Lund O, Nielsen M (2008) NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res W509-W512.
28. Mardis ER, Wilson RK (2009) Cancer genome sequencing: a review. Hum Mol Genet 18(R2): R163-R168.
29. Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, Arthur CD,White JM, Chen YS, Shea LK, Hundal J,Wendl MC, Demeter R, Wylie T, Allison JP, Smyth MJ, Old LJ, Mardis ER, Schreiber RD (2012) Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482(7385): 400-404.
30. Overwijk WW, Restifo NP (2001) B16 as a mouse model for human melanoma. Curr Protoc Immunol Chapter 20: Unit 20 1.
31. Rahma OE, Ashtar E, Ibrahim R, Toubaji A, Gause B, Herrin VE, LinehanWM, Steinberg SM, Grollman F, Grimes G, Bernstein SA, Berzofsky JA, Khleif SN (2010) A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic renal cell carcinoma. J Transl Med 8: 8.
32. Rammensee HG, Singh-Jasuja H (2013) HLA ligandome tumor antigen discovery for personalized vaccine approach. Expert Rev Vaccines 12(10): 1211-1217.
33. Roth J, Dittmer D, Rea D, Tartaglia J, Paoletti E, Levine AJ (1996) p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge. Proc Natl Acad Sci USA 93(10): 4781-4786.
34. Schlake T, Thess A, Fotin-Mleczek M, Kallen KJ (2012) Developing mRNA-vaccine technologies. RNA Biol 9(11): 1319-1330.
35. Scholtalbers J, Rossler J, Sorn P, de Graaf J, Boisguerin V, Castle J, Sahin U (2013) Galaxy LIMS for next-generation sequencing. Bioinformatics 29: 1233-1234.
36. Segal NH, Parsons DW, Peggs KS, Velculescu V, Kinzler KW, Vogelstein B, Allison JP (2008) Epitope landscape in breast and colorectal cancer. Cancer Res 68(3): 889-892.
37. Shah SP, Morin RD, Khattra J, Prentice L, Pugh T, Burleigh A, Delaney A, Gelmon K, Guliany R, Senz J, Steidl C, Holt RA, Jones S, Sun M, Leung G, Moore R, Severson T, Taylor GA, Teschendorff AE, Tse K, Turashvili G, Varhol R, Warren RL, Watson P, Zhao Y, Caldas C, Huntsman D, Hirst M, Marra MA, Aparicio S (2009) Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 461(7265): 809-813.
38. Srivastava N, Srivastava PK (2009) Modeling the repertoire of true tumor-specific MHC I epitopes in a human tumor. PLoS One 4(7): e6094.
39. Stratton MR (2011) Exploring the genomes of cancer cells: progress and promise. Science 331(6024): 1553-1558.
40. Weide B, Garbe C, Rammensee HG, Pascolo S (2008) Plasmid DNA-and messenger RNA-based anti-cancer vaccination. Immunol Lett 115(1): 33-42.
41. Yajima N, Yamanaka R, Mine T, Tsuchiya N, Homma J, Sano M, Kuramoto T, Obata Y, Komatsu N, Arima Y, Yamada A, Shigemori M, Itoh K, Tanaka R (2005) Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin Cancer Res 11(16): 5900-5911.